Loading…
Reported covered position: Policy Director, Republican Whip Steve Scalise, professional staff House Ways and Means Committee, Chief of Staff, Rep. Dan Miller, Budget Associate, House Budget Committee
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: THE BUSINESS ROUNDTABLE, INC. · Firm: S-3 GROUP
Issues related to corporate and international tax; H.R.1 One Big Beautiful Bill Act of 2025
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: THE BUSINESS ROUNDTABLE, INC. · Firm: S-3 GROUP
Issues related to corporate and international tax; H.R.1 One Big Beautiful Bill Act of 2025
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
INTERFOR CORPORATION via S-3 GROUP
2026 · third_quarter · Q3
Issues related to lumber tariffs
Issues related to housing policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
| KPMG LLP | 18 | 2022–2026 |
| ALLIANCE OF COMMUNITY HEALTH PLANS | 17 | 2023–2026 |
| AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. | 17 | 2022–2026 |
| MCKINSEY & COMPANY | 17 | 2022–2026 |
| AMERICAN OPTOMETRIC ASSOCIATION | 16 | 2023–2026 |
| LVMH MOET HENNESSY LOUIS VUITTON INC. | 16 | 2023–2026 |
| NATIONAL FOOTBALL LEAGUE | 16 | 2022–2026 |
| THE BUSINESS ROUNDTABLE, INC. | 16 | 2023–2026 |
| BAXTER HEALTHCARE CORPORATION | 15 | 2023–2026 |
| S&P GLOBAL | 15 | 2023–2026 |
| SANDOZ INC. | 14 | 2023–2026 |
| H&R BLOCK | 13 | 2023–2026 |
| MICRON TECHNOLOGY, INC. | 11 | 2022–2024 |
| ROCKET LIMITED PARTNERSHIP (F/K/A RKT HOLDINGS, LLC) | 11 | 2020–2026 |
| T-MOBILE USA, INC. | 11 | 2022–2024 |
| AIR LINE PILOTS ASSOCIATION | 10 | 2023–2026 |
| HEALTH SUPPLY US | 10 | 2023–2026 |
| ROCK CENTRAL | 10 | 2022–2024 |
| ACTUM OBO ILLUMINA, INC. | 9 | 2024–2025 |
| ORCHARD THERAPEUTICS NORTH AMERICA | 9 | 2024–2026 |
| PATTERN ENERGY GROUP SERVICES LP | 9 | 2025–2026 |
| ABBOTT LABORATORIES | 8 | 2025–2026 |
| BLOOM ENERGY CORPORATION | 8 | 2025–2026 |
| COUNCIL ON FOUNDATIONS INC. | 8 | 2025–2026 |
| DAVITA, INC. | 8 | 2025–2026 |
| INTEL CORPORATION | 8 | 2025–2026 |
| LOWE'S COMPANIES INC | 8 | 2025–2026 |
| MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 8 | 2025–2026 |
| MONDELEZ INTERNATIONAL | 8 | 2025–2026 |
| OSHKOSH CORPORATION | 8 | 2025–2026 |
| CONSUMER TECHNOLOGY ASSOCIATION | 7 | 2025–2026 |
| GOODRX | 7 | 2025–2026 |
| JUUL LABS | 7 | 2022–2023 |
| SAZERAC COMPANY, INC. | 7 | 2025–2026 |
| STANDARD INDUSTRIES LTD. | 7 | 2023–2024 |
| XCEL ENERGY SERVICES, INC. | 7 | 2025–2026 |
| CTIA - THE WIRELESSS ASSOCIATION | 6 | 2025–2026 |
| ASSOCIATION OF HOME APPLIANCE MANUFACTURERS | 5 | 2023–2024 |
| ESSITY NORTH AMERICA INC. | 5 | 2025–2026 |
| HEALTH INDUSTRY DISTRIBUTORS ASSOCIATION | 5 | 2025 |
| SYNOPSYS, INC. | 5 | 2023 |
| VERAX BIOMEDICAL | 5 | 2022–2023 |
| BRUNSWICK CORPORATION | 4 | 2025 |
| CONOCOPHILLIPS | 4 | 2026 |
| JAPAN TOBACCO INTERNATIONAL USA INC. | 4 | 2026 |
| NOVO NORDISK, INC. | 4 | 2026 |
| ALZHEIMER'S ASSOCIATION | 3 | 2022 |
| CONSTELLATION BRANDS | 3 | 2026 |
| CUE HEALTH INC | 3 | 2022–2023 |
| GENERAL MOTORS | 3 | 2022 |
| GENEVANT SCIENCES, INC. | 3 | 2023 |
| INTERFOR CORPORATION | 3 | 2026 |
| LEGO SYSTEMS, INC. | 3 | 2025 |
| WALGREEN COMPANY | 3 | 2026 |
| WTA TOUR, INC. | 3 | 2023 |
| COMMONWEALTH LNG | 2 | 2024 |
| DUKE ENERGY CORPORATION | 2 | 2026 |
H.R. 2405 (White Oak Resilience Act) and S. 476 (White Oak Resilience Act) relating to the availability of white oak; forestry-related provisions in agriculture-related legislation; H.R. 471 (Fix Our Forests Act); issues related to intoxicating hemp
H.R. 2405 (White Oak Resilience Act) and S. 476 (White Oak Resilience Act) relating to the availability of white oak; forestry-related provisions in agriculture-related legislation; H.R. 471 (Fix Our Forests Act); issues related to intoxicating hemp
H.R. 2405 (White Oak Resilience Act) and S. 476 (White Oak Resilience Act) relating to the availability of white oak; forestry-related provisions in agriculture-related legislation; H.R. 471 (Fix Our Forests Act); issues related to intoxicating hemp
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Reserved for the Speaker.
Client: AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · Firm: S-3 GROUP
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019
Reserved for the Speaker.
Client: AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · Firm: S-3 GROUP
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019
H.R. 2405 (White Oak Resilience Act) and S. 476 (White Oak Resilience Act) relating to the availability of white oak; forestry-related provisions in agriculture-related legislation; H.R. 471 (Fix Our Forests Act); issues related to intoxicating hemp
H.R. 2405 (White Oak Resilience Act) and S. 476 (White Oak Resilience Act) relating to the availability of white oak; forestry-related provisions in agriculture-related legislation; H.R. 471 (Fix Our Forests Act); issues related to intoxicating hemp
H.R. 2405 (White Oak Resilience Act) and S. 476 (White Oak Resilience Act) relating to the availability of white oak; forestry-related provisions in agriculture-related legislation; H.R. 471 (Fix Our Forests Act); issues related to intoxicating hemp
General healthcare policy issues, including Medicare Advantage, Medicare Part D and other payer policy matters, and health care clinical services; S.1105: No Unreasonable Payments, Coding, or Diagnoses for the Elderly Act; PL 119-21: One Big Beautiful Bill Act
General healthcare policy issues, including Medicare Advantage, Medicare Part D and other payer policy matters, and health care clinical services; S.1105: No Unreasonable Payments, Coding, or Diagnoses for the Elderly Act; PL 119-21: One Big Beautiful Bill Act
General healthcare policy issues, including Medicare Advantage, Medicare Part D and other payer policy matters, and health care clinical services; S.1105: No Unreasonable Payments, Coding, or Diagnoses for the Elderly Act; PL 119-21: One Big Beautiful Bill Act
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Dental and Optometric Care Access Act; Vision Lab Choice Act S 1716
Dental and Optometric Care Access Act; Vision Lab Choice Act S 1716
H.R. 2405 (White Oak Resilience Act) and S. 476 (White Oak Resilience Act) relating to the availability of white oak; forestry-related provisions in agriculture-related legislation; H.R. 471 (Fix Our Forests Act); issues related to intoxicating hemp
H.R. 2405 (White Oak Resilience Act) and S. 476 (White Oak Resilience Act) relating to the availability of white oak; forestry-related provisions in agriculture-related legislation; H.R. 471 (Fix Our Forests Act); issues related to intoxicating hemp
H.R. 2405 (White Oak Resilience Act) and S. 476 (White Oak Resilience Act) relating to the availability of white oak; forestry-related provisions in agriculture-related legislation; H.R. 471 (Fix Our Forests Act); issues related to intoxicating hemp
Prescription Drug Price Relief Act of 2019
Client: AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · Firm: S-3 GROUP
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019
Prescription Drug Price Relief Act of 2019
Client: AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · Firm: S-3 GROUP
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: THE BUSINESS ROUNDTABLE, INC. · Firm: S-3 GROUP
Issues related to corporate and international tax; H.R.1 One Big Beautiful Bill Act of 2025
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: THE BUSINESS ROUNDTABLE, INC. · Firm: S-3 GROUP
Issues related to corporate and international tax; H.R.1 One Big Beautiful Bill Act of 2025
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: THE BUSINESS ROUNDTABLE, INC. · Firm: S-3 GROUP
Issues related to corporate and international tax; H.R.1 One Big Beautiful Bill Act of 2025
H.R. 409 relating to repeal of limitation on cover over of distilled spirits taxes to the Virgin Island and Puerto Rico; H.R. 1175/S.362 (Craft Beverage Modernization and Tax Reform Act)
H.R. 409 relating to repeal of limitation on cover over of distilled spirits taxes to the Virgin Island and Puerto Rico; H.R. 1175/S.362 (Craft Beverage Modernization and Tax Reform Act)
H.R. 409 relating to repeal of limitation on cover over of distilled spirits taxes to the Virgin Island and Puerto Rico; H.R. 1175/S.362 (Craft Beverage Modernization and Tax Reform Act)
H.R. 409 relating to repeal of limitation on cover over of distilled spirits taxes to the Virgin Island and Puerto Rico; H.R. 1175/S.362 (Craft Beverage Modernization and Tax Reform Act)
Reserved for the Speaker.
Client: AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · Firm: S-3 GROUP
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019
Reserved for the Speaker.
Client: AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · Firm: S-3 GROUP
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019
Reserved for the Speaker.
Client: AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · Firm: S-3 GROUP
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019
Reserved for the Speaker.
Client: AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · Firm: S-3 GROUP
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019
H.R. 409 relating to repeal of limitation on cover over of distilled spirits taxes to the Virgin Island and Puerto Rico; H.R. 1175/S.362 (Craft Beverage Modernization and Tax Reform Act)
H.R. 409 relating to repeal of limitation on cover over of distilled spirits taxes to the Virgin Island and Puerto Rico; H.R. 1175/S.362 (Craft Beverage Modernization and Tax Reform Act)
H.R. 409 relating to repeal of limitation on cover over of distilled spirits taxes to the Virgin Island and Puerto Rico; H.R. 1175/S.362 (Craft Beverage Modernization and Tax Reform Act)
H.R. 409 relating to repeal of limitation on cover over of distilled spirits taxes to the Virgin Island and Puerto Rico; H.R. 1175/S.362 (Craft Beverage Modernization and Tax Reform Act)
General healthcare policy issues, including Medicare Advantage, Medicare Part D and other payer policy matters, and health care clinical services; S.1105: No Unreasonable Payments, Coding, or Diagnoses for the Elderly Act; PL 119-21: One Big Beautiful Bill Act
General healthcare policy issues, including Medicare Advantage, Medicare Part D and other payer policy matters, and health care clinical services; S.1105: No Unreasonable Payments, Coding, or Diagnoses for the Elderly Act; PL 119-21: One Big Beautiful Bill Act
General healthcare policy issues, including Medicare Advantage, Medicare Part D and other payer policy matters, and health care clinical services; S.1105: No Unreasonable Payments, Coding, or Diagnoses for the Elderly Act; PL 119-21: One Big Beautiful Bill Act
A bill to allow certain Federal minerals to be mined consistent with the Bull Mountains Mining Plan Modification, and for other purposes.
Client: SAZERAC COMPANY, INC. · Firm: S-3 GROUP
H.R. 409 relating to repeal of limitation on cover over of distilled spirits taxes to the Virgin Island and Puerto Rico; H.R. 1175/S.362 (Craft Beverage Modernization and Tax Reform Act)
A bill to allow certain Federal minerals to be mined consistent with the Bull Mountains Mining Plan Modification, and for other purposes.
Client: SAZERAC COMPANY, INC. · Firm: S-3 GROUP
H.R. 409 relating to repeal of limitation on cover over of distilled spirits taxes to the Virgin Island and Puerto Rico; H.R. 1175/S.362 (Craft Beverage Modernization and Tax Reform Act)
A bill to allow certain Federal minerals to be mined consistent with the Bull Mountains Mining Plan Modification, and for other purposes.
Client: SAZERAC COMPANY, INC. · Firm: S-3 GROUP
H.R. 409 relating to repeal of limitation on cover over of distilled spirits taxes to the Virgin Island and Puerto Rico; H.R. 1175/S.362 (Craft Beverage Modernization and Tax Reform Act)
A bill to allow certain Federal minerals to be mined consistent with the Bull Mountains Mining Plan Modification, and for other purposes.
Client: SAZERAC COMPANY, INC. · Firm: S-3 GROUP
H.R. 409 relating to repeal of limitation on cover over of distilled spirits taxes to the Virgin Island and Puerto Rico; H.R. 1175/S.362 (Craft Beverage Modernization and Tax Reform Act)
Tax Relief for American Families and Workers Act of 2024
Client: THE BUSINESS ROUNDTABLE, INC. · Firm: S-3 GROUP
Issues related to corporate and international tax; H.R. 7024 Tax Relief for American Families and Workers Act of 2024
Prescription Drug Price Relief Act of 2019
Client: AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · Firm: S-3 GROUP
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019
Prescription Drug Price Relief Act of 2019
Client: AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · Firm: S-3 GROUP
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019
Prescription Drug Price Relief Act of 2019
Client: AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · Firm: S-3 GROUP
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019
Prescription Drug Price Relief Act of 2019
Client: AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · Firm: S-3 GROUP
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019
Reserved for the Speaker.
Client: AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · Firm: S-3 GROUP
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019; issues related to Safe Step Act
Reserved for the Speaker.
Client: AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · Firm: S-3 GROUP
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019; issues related to Safe step Act
Reserved for the Speaker.
Client: AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · Firm: S-3 GROUP
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019; issues related to Safe Step Act
Reserved for the Speaker.
Client: AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · Firm: S-3 GROUP
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019; issues related to Safe Step Act
Tax Relief for American Families and Workers Act of 2024
Client: STANDARD INDUSTRIES LTD. · Firm: S-3 GROUP
HR 7024, The Tax Relief for American Families and Workers Act of 2024
Tax Relief for American Families and Workers Act of 2024
Client: STANDARD INDUSTRIES LTD. · Firm: S-3 GROUP
HR 7024, The Tax Relief for American Families and Workers Act of 2024
Tax Relief for American Families and Workers Act of 2024
Client: THE BUSINESS ROUNDTABLE, INC. · Firm: S-3 GROUP
Issues related to corporate and international tax; H.R. 7024, Tax Relief for American Families and Workers Act of 2024
Tax Relief for American Families and Workers Act of 2024
Client: THE BUSINESS ROUNDTABLE, INC. · Firm: S-3 GROUP
Issues related to tax; H.R. 7024, Tax Relief for American Families and Workers Act of 2024
Tax Relief for American Families and Workers Act of 2024
Client: THE BUSINESS ROUNDTABLE, INC. · Firm: S-3 GROUP
Issues related to corporate and international tax; H.R. 7024, Tax Relief for American Families and Workers Act of 2024
Tax Relief for American Families and Workers Act of 2024
Client: THE BUSINESS ROUNDTABLE, INC. · Firm: S-3 GROUP
Issues related to corporate and international tax; H.R. 7024, Tax Relief for American Families and Workers Act of 2024
Tax Relief for American Families and Workers Act of 2024
Client: STANDARD INDUSTRIES LTD. · Firm: S-3 GROUP
HR 7024, The Tax Relief for American Families and Workers Act of 2024
Tax Relief for American Families and Workers Act of 2024
Client: STANDARD INDUSTRIES LTD. · Firm: S-3 GROUP
HR 7024, The Tax Relief for American Families and Workers Act of 2024
National Defense Authorization Act for Fiscal Year 2025
Client: ROCKET LIMITED PARTNERSHIP F/K/A RKT HOLDINGS, LLC · Firm: S-3 GROUP
Mortgage servicing and data privacy issues; general FHA, FHFA, VA, USDA issues, oversight of federal housing policy; general diversity and inclusion issues; S.4638 National Defense Authorization Act for Fiscal Year 2025
National Defense Authorization Act for Fiscal Year 2025
Client: ROCKET LIMITED PARTNERSHIP F/K/A RKT HOLDINGS, LLC · Firm: S-3 GROUP
Mortgage servicing and data privacy issues; general FHA, FHFA, VA, USDA issues, oversight of federal housing policy; S.4638 National Defense Authorization Act for Fiscal Year 2025
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: ROCK CENTRAL · Firm: S-3 GROUP
General tax reform; qualified office conversion tax credit; S. Con. Res. 14, FY 2022 Budget Resolution
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: ROCKET LIMITED PARTNERSHIP F/K/A RKT HOLDINGS, LLC · Firm: S-3 GROUP
Mortgage servicing and data privacy issues; general FHA, FHFA, VA, USDA issues; oversight of federal housing policy; general diversity and inclusion issues; general tax reform; qualified office conversion tax credit; S.Con.Res. 14, FY2022 Budget Resolution
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: ROCKET LIMITED PARTNERSHIP F/K/A RKT HOLDINGS, LLC · Firm: S-3 GROUP
Mortgage servicing and data privacy issues; general FHA, FHFA, VA, USDA issues; oversight of federal housing policy; general diversity and inclusion issues; general tax reform; qualified office conversion tax credit; S.Con.Res. 14, FY2022 Budget Resolution
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: ROCK CENTRAL · Firm: S-3 GROUP
General tax reform; qualified office conversion tax credit; S. Con. Res. 14, FY 2022 Budget Resolution
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: ROCKET LIMITED PARTNERSHIP F/K/A RKT HOLDINGS, LLC · Firm: S-3 GROUP
General tax reform; qualified office conversion tax credit; S. Con. Res. 14, FY 2022 Budget Resolution
Prescription Drug Price Relief Act of 2019
Client: AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · Firm: S-3 GROUP
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019; issues related to Safe step Act
Prescription Drug Price Relief Act of 2019
Client: AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · Firm: S-3 GROUP
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019; issues related to Safe Step Act
Prescription Drug Price Relief Act of 2019
Client: AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · Firm: S-3 GROUP
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019; issues related to Safe Step Act
Prescription Drug Price Relief Act of 2019
Client: AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · Firm: S-3 GROUP
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019; issues related to Safe Step Act
National Defense Authorization Act for Fiscal Year 2024
Client: SYNOPSYS, INC. · Firm: S-3 GROUP
Issues related to ensuring a trustworthy supply of semiconductors to the Department of Defense; FY2024 S.2226 National Defense Authorization Act (NDAA); FY2024 H.R. 2670 National Defense Authorization Act (NDAA)
National Defense Authorization Act for Fiscal Year 2024
Client: SYNOPSYS, INC. · Firm: S-3 GROUP
Issues related to ensuring a trustworthy supply of semiconductors to the Department of Defense; FY2024 S.2226 National Defense Authorization Act (NDAA); FY2024 H.R. 2670 National Defense Authorization Act (NDAA)
American Innovation and R&D Competitiveness Act of 2023
Client: SYNOPSYS, INC. · Firm: S-3 GROUP
Importance of electronic design automation (EDA) and semiconductor IP to US competitiveness; issues related to EDA and IP research and development; implementation of the CHIPS and Science Act (P.L. 117-167); restored deduction for R&D expenditures; H.R. 2673 American Innovation and R&D Competitiveness Act of 2023; S.866 American Innovation and Jobs Act
American Innovation and R&D Competitiveness Act of 2023
Client: SYNOPSYS, INC. · Firm: S-3 GROUP
Importance of electronic design automation (EDA) and semiconductor IP to US competitiveness; issues related to EDA and IP research and development; implementation of the CHIPS and Science Act (P.L. 117-167); restored deduction for R&D expenditures; H.R. 2673 American Innovation and R&D Competitiveness Act of 2023; S.866 American Innovation and Jobs Act
Reserved for the Speaker.
Client: AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · Firm: S-3 GROUP
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019; issues related to Safe step Act
Reserved for the Speaker.
Client: AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · Firm: S-3 GROUP
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019; issues related to Safe step Act
Reserved for the Speaker.
Client: AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · Firm: S-3 GROUP
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019; issues related to Safe step Act
Reserved for the Speaker.
Client: AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · Firm: S-3 GROUP
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019; issues related to Safe step Act
Risk-proportionate regulation for electronic nicotine delivery system products to advance tobacco harm reduction for adult smokers and policies to combat underage use; issues related to enforcement of illicit tobacco products, including importation of counterfeit products; issues related to taxation and user fees for tobacco and electronic nicotine delivery system products; discussions related to implementation of Public Law 111-31, the Family Smoking Prevention and Tobacco Control Act, and PMTA submissions for deemed tobacco products; H.R. 901, the Disposable ENDS Product Enforcement Act of 2023
Risk-proportionate regulation for electronic nicotine delivery system products to advance tobacco harm reduction for adult smokers and policies to combat underage use; issues related to enforcement of illicit tobacco products, including importation of counterfeit products; issues related to taxation and user fees for tobacco and electronic nicotine delivery system products; discussions related to implementation of Public Law 111-31, the Family Smoking Prevention and Tobacco Control Act, and PMTA submissions for deemed tobacco products; H.R. 901, the Disposable ENDS Product Enforcement Act of 2023
Risk-proportionate regulation for electronic nicotine delivery system products to advance tobacco harm reduction for adult smokers and policies to combat underage use; issues related to enforcement of illicit tobacco products, including importation of counterfeit products; issues related to taxation and user fees for tobacco and electronic nicotine delivery system products; discussions related to implementation of Public Law 111-31, the Family Smoking Prevention and Tobacco Control Act, and PMTA submissions for deemed tobacco products; H.R. 901, the Disposable ENDS Product Enforcement Act of 2023
Risk-proportionate regulation for electronic nicotine delivery system products to advance tobacco harm reduction for adult smokers and policies to combat underage use; issues related to enforcement of illicit tobacco products, including importation of counterfeit products; issues related to taxation and user fees for tobacco and electronic nicotine delivery system products; discussions related to implementation of Public Law 111-31, the Family Smoking Prevention and Tobacco Control Act, and PMTA submissions for deemed tobacco products; H.R. 901, the Disposable ENDS Product Enforcement Act of 2023
National Defense Authorization Act for Fiscal Year 2024
Client: SYNOPSYS, INC. · Firm: S-3 GROUP
Issues related to ensuring a trustworthy supply of semiconductors to the Department of Defense; FY2024 S.2226 National Defense Authorization Act (NDAA); FY2024 H.R. 2670 National Defense Authorization Act (NDAA)
National Defense Authorization Act for Fiscal Year 2024
Client: SYNOPSYS, INC. · Firm: S-3 GROUP
Issues related to ensuring a trustworthy supply of semiconductors to the Department of Defense; FY2024 S.2226 National Defense Authorization Act (NDAA); FY2024 H.R. 2670 National Defense Authorization Act (NDAA)
Importance of electronic design automation (EDA) and semiconductor IP to US competitiveness; issues related to EDA and IP research and development; implementation of the CHIPS and Science Act (P.L. 117-167); restored deduction for R&D expenditures; H.R. 2673 American Innovation and R&D Competitiveness Act of 2023; S.866 American Innovation and Jobs Act
Importance of electronic design automation (EDA) and semiconductor IP to US competitiveness; issues related to EDA and IP research and development; implementation of the CHIPS and Science Act (P.L. 117-167); restored deduction for R&D expenditures; H.R. 2673 American Innovation and R&D Competitiveness Act of 2023; S.866 American Innovation and Jobs Act
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: ROCK CENTRAL · Firm: S-3 GROUP
General tax reform; qualified office conversion tax credit; S. Con. Res. 14, FY 2022 Budget Resolution
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: ROCK CENTRAL · Firm: S-3 GROUP
General tax reform; qualified office conversion tax credit; S. Con. Res. 14, FY 2022 Budget Resolution
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: ROCK CENTRAL · Firm: S-3 GROUP
General tax reform; qualified office conversion tax credit; S. Con. Res. 14, FY 2022 Budget Resolution
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: ROCK CENTRAL · Firm: S-3 GROUP
General tax reform; qualified office conversion tax credit; S. Con. Res. 14, FY 2022 Budget Resolution
Prescription Drug Price Relief Act of 2019
Client: AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · Firm: S-3 GROUP
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019; issues related to Safe step Act
Prescription Drug Price Relief Act of 2019
Client: AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · Firm: S-3 GROUP
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019; issues related to Safe step Act
Prescription Drug Price Relief Act of 2019
Client: AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · Firm: S-3 GROUP
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019; issues related to Safe step Act
Prescription Drug Price Relief Act of 2019
Client: AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · Firm: S-3 GROUP
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019; issues related to Safe step Act
Risk-proporitionate regulation for electronic nicotine delivery system products to advance tobacco harm reduction for adult smokers and policies to combat underage use; issues related to enforcement of illicit tobacco products, including importation of counterfeit products; and unregulated nicotine products; issues related to taxation and user fees for tobacco and electronic nicotine delivery system products; issues related to regulation of synthetic nicotine products; discussions related to implementation of Public Law 111-31, the Family Smoking Prevention and Tobacco Control Act, and PMTA submissions for deemed tobacco products; H.R. 2125/H.r. 2185/S. 2622, the Quit Because of COVID-19 Act; H.R. 2786/S.1314, the Tobacco Tax Equity Act of 2021; H.R. 3051, the End ENDS Act of 2021; H.R. 3226, the Accurate Reporting of Smoking Variants Act of 2021; H.R. 3407/S.411, the Mothers and Offspring Mortality and Morbidity Awareness Act; H.R. 4629/S. 2445, the Resources to Prevent Youth Vaping Act; H.R. 5546/S. 2974, the PROTECT Act
Risk-proporitionate regulation for electronic nicotine delivery system products to advance tobacco harm reduction for adult smokers and policies to combat underage use; issues related to enforcement of illicit tobacco products, including importation of counterfeit products; and unregulated nicotine products; issues related to taxation and user fees for tobacco and electronic nicotine delivery system products; issues related to regulation of synthetic nicotine products; discussions related to implementation of Public Law 111-31, the Family Smoking Prevention and Tobacco Control Act, and PMTA submissions for deemed tobacco products; H.R. 2125/H.r. 2185/S. 2622, the Quit Because of COVID-19 Act; H.R. 2786/S.1314, the Tobacco Tax Equity Act of 2021; H.R. 3051, the End ENDS Act of 2021; H.R. 3226, the Accurate Reporting of Smoking Variants Act of 2021; H.R. 3407/S.411, the Mothers and Offspring Mortality and Morbidity Awareness Act; H.R. 4629/S. 2445, the Resources to Prevent Youth Vaping Act; H.R. 5546/S. 2974, the PROTECT Act
2026 · third_quarter · Q3
Commercial issues related to the beverage alcohol industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK, INC. via S-3 GROUP
2026 · third_quarter · Q3
Issues related to tariffs and importation of counterfeit drugs.
Issues related to drug pricing and implementation of the Inflation Reduction Act; coverage of anti-obesity medications; pharmacy benefit management reforms; Most Favored Nation drug pricing.
Issues related to compounding and counterfeit drugs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
Issues regarding permitting reform
Issues regarding permitting reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JAPAN TOBACCO INTERNATIONAL USA INC. via S-3 GROUP
2026 · third_quarter · Q3
Monitor trade, tax issues and regulations
Monitor trade, tax issues and regulations
Monitor trade, tax issues and regulations
Monitor trade, tax issues and regulations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ESSITY NORTH AMERICA INC. via S-3 GROUP
2026 · third_quarter · Q3
Advocacy related to product regulatory issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues regarding lower prescription drug prices for patients
Issues regarding lower prescription drug prices for patients
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OSHKOSH CORPORATION via S-3 GROUP
2026 · third_quarter · Q3
US manufacturing and international competitiveness
US manufacturing and international competitiveness
US manufacturing and international competitiveness
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLOOM ENERGY CORPORATION via S-3 GROUP
2026 · third_quarter · Q3
Issues related to fuel cell tax credits
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COUNCIL ON FOUNDATIONS INC. via S-3 GROUP
2026 · third_quarter · Q3
Strategies and policy advice on tax policy matters with respect to the philanthropic sector
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MONDELEZ INTERNATIONAL via S-3 GROUP
2026 · third_quarter · Q3
Issues related to food and nutrition policy
Issues related to food and nutrition policy
Issues related to trade, taxes, and tariffs
ABBOTT LABORATORIES via S-3 GROUP
2026 · third_quarter · Q3
Issues related to infant formula
Proposals to reform domestic and international tax structures
Equitable Access to Community Pharmacist Services Act
PATTERN ENERGY GROUP SERVICES LP via S-3 GROUP
2026 · third_quarter · Q3
Issues regarding renewable energy and electronic transmission projects
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
Issues related to dialysis payment policy, including End Stage Renal Disease (ESRD) Perspective Payment System (PPS)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS INSTITUTE OF TECHNOLOGY via S-3 GROUP
2026 · third_quarter · Q3
Issues related to higher education
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LOWE'S COMPANIES INC. via S-3 GROUP
2026 · third_quarter · Q3
Issues related to corporate tax reform
Issues related to corporate tax reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via S-3 GROUP
2026 · third_quarter · Q3
Issues related to the provider status of pharmacists under Medicare Part B
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Issues related to pharmacy, pharmacist provider status, pharmacy benefit managers, Medicare reimbursement, and pharmaceutical supply chain transparency
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FORIS DAX, INC. D/B/A CRYPTO.COM via S-3 GROUP
2026 · third_quarter · 3T
Advocating on behalf of users of cryptocurrency and the process of how consumers invest, save, trade, in the digital place
Advocating on behalf of users of cryptocurrency and the process of how consumers invest, save, trade, in the digital place
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTEL CORPORATION via S-3 GROUP
2026 · third_quarter · Q3
Issues related to trade and tariffs
Issues related to support for domestic chipmakers in NDAA
Issues related to Inter Partes Review and patent litigation at the ITC
ORCHARD THERAPEUTICS NORTH AMERICA via S-3 GROUP
2026 · third_quarter · Q3
Issues related to funding for newborn screenings for metachromatic leukodystrophy
Issues related to funding for newborn screenings for metachromatic leukodystrophy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROCKET LIMITED PARTNERSHIP F/K/A RKT HOLDINGS, LLC via S-3 GROUP
2026 · third_quarter · Q3
Mortgage servicing and data privacy issues; general FHA, FHFA, VA, USDA issues; oversight of federal housing policy
General tax reform; qualified office conversion tax credit
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTH SUPPLY US via S-3 GROUP
2026 · third_quarter · Q3
Domestic industrial base and public health supply chain issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to tax filing
Issues related to tax filing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANDOZ INC. via S-3 GROUP
2026 · third_quarter · Q3
Issues and legislative proposals on biosimilars and generics medicines, including but not limited to generics and biosimilar sustainability, pharmaceutical supply chain security, drug shortages, interchangeability, patent litigation, and PBM reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AIR LINE PILOTS ASSOCIATION via S-3 GROUP
2026 · third_quarter · Q3
Issues specific to aviation and pilots
General aviation issues
Aviation safety; single pilot operations
BAXTER HEALTHCARE CORPORATION via S-3 GROUP
2026 · third_quarter · Q3
Promote kidney care and positive patient outcomes
Issues relating to safe mobility; issues relating to pandemic all-hazards preparedness act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONSUMER TECHNOLOGY ASSOCIATION via S-3 GROUP
2026 · third_quarter · Q3
General educational meetings on policy issues impacting tech platforms
Monitor issues related to consumer data privacy, and children's privacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE OF COMMUNITY HEALTH PLANS via S-3 GROUP
2026 · third_quarter · Q3
Issues related to healthcare; Medicare Advantage and Medicaid
Issues related to healthcare; Medicare Advantage and Medicaid
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE BUSINESS ROUNDTABLE, INC. via S-3 GROUP
2026 · third_quarter · Q3
Issues related to trade and tariff policy; issues relating to Russia sanctions
Tax, trade, economic issues, and government funding
Issues relating to artificial intelligence
AMERICAN OPTOMETRIC ASSOCIATION via S-3 GROUP
2026 · third_quarter · Q3
Dental and Optometric Care Access Act; Vision Lab Choice Act S 1716
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
General healthcare policy issues, including Medicare Advantage, Medicare Part D and other payer policy matters, and health care clinical services; S.1105: No Unreasonable Payments, Coding, or Diagnoses for the Elderly Act; PL 119-21: One Big Beautiful Bill Act
Issued related to PL 119-21: One Big Beautiful Bill Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FORIS DAX, INC. D/B/A CRYPTO.COM via S-3 GROUP
2026 · third_quarter · Q3
Advocating on behalf of users of cryptocurrency and the process of how consumers invest, save, trade, in the digital place
Advocating on behalf of users of cryptocurrency and the process of how consumers invest, save, trade, in the digital place
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MCKINSEY & COMPANY via S-3 GROUP
2026 · third_quarter · Q3
Raising awareness related to company activities and business
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE TO MODERNIZE PRESCRIBING INFORMATION via S-3 GROUP
2026 · third_quarter · Q3
Advocating for electronic labeling for prescribers only
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAZERAC COMPANY, INC. via S-3 GROUP
2026 · third_quarter · Q3
Proposed tariffs and impact on exports and imports of distilled spirits.
Food and beverage policy issues, including U.S. dietary guidelines; support appropriations or U.S. Alcohol and Tobacco Tax and Trade Bureau; issues pertaining to the alcohol industry.
Issues related to duty drawback and alcohol taxes.
AMERICAN PETROLEUM INSTITUTE via S-3 GROUP
2026 · third_quarter · Q3
Issues concerning oil and gas production
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. via S-3 GROUP
2026 · third_quarter · Q3
Issues related to Rx drug pricing
Issues related to health care research
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DUKE ENERGY CORPORATION via S-3 GROUP
2026 · third_quarter · Q3
Regulatory issues confronting the electric utility and natural gas sectors
Regulatory issues confronting the electric utility and natural gas sectors
Regulatory issues confronting the electric utility and natural gas sectors
Issues related to financial services and accounting
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CTIA THE WIRELESS ASSOCIATION via S-3 GROUP
2026 · third_quarter · Q3
Issues related to wireless policy, including spectrum, broadband funding, 5G, and privacy; issues related to the use of contraband phones in correctional facilities; issues related to artificial intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LVMH MOET HENNESSY LOUIS VUITTON INC. via S-3 GROUP
2026 · third_quarter · Q3
Federal policy relating to general tax policy, trade agreements, consumer protection, and general regulatory matters impacting the fashion, wines and spirits, perfume and cosmetic, watch and jewelry, and related luxury products industry
Federal policy relating to general tax policy, trade agreements, consumer protection, and general regulatory matters impacting the fashion, wines and spirits, perfume and cosmetic, watch and jewelry, and related luxury products industry
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, White House Office
JPMORGAN CHASE HOLDINGS LLC via S-3 GROUP
2026 · third_quarter · Q3
Issues related to banking and financial services and Financial Services Appropriations
Issues related to the budget and the implementation of financial services legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
XCEL ENERGY SERVICES, INC. via S-3 GROUP
2026 · third_quarter · Q3
Electric and gas utility issues under the tax code and the Federal Power Act, including issues related to renewables
Electric and gas utility issues under the tax code and the Federal Power Act, including issues related to renewables
Electric and gas utility issues under the tax code and the Federal Power Act, including issues related to renewables
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S&P GLOBAL via S-3 GROUP
2026 · third_quarter · Q3
Issues related to infrastructure
Issues related to credit rating agencies and commodity/ financial derivatives and benchmarks; privacy issues
Issues related to the pricing of aluminum
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KOCH GOVERNMENT AFFAIRS, LLC FKA KOCH COMPANIES PUBLIC SECTOR, LLC via S-3 GROUP
2026 · third_quarter · Q3
Legislative issues related to energy and the environment; issues related to congressional funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERFOR CORPORATION via S-3 GROUP
2026 · second_quarter · Q2
Issues related to lumber tariffs
Issues related to housing policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERFOR CORPORATION via S-3 GROUP
2026 · second_quarter · RR
Issues related to lumber tariffs and US housing policy
Issues related to lumber tariffs and US housing policy
HEALTH SUPPLY US via S-3 GROUP
2026 · second_quarter · Q2
Domestic industrial base and public health supply chain issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTH SUPPLY US via S-3 GROUP
2026 · second_quarter · RA
Domestic industrial base and public health supply chain issues
CONSTELLATION BRANDS via S-3 GROUP
2026 · second_quarter · Q2
Commercial issues related to the beverage alcohol industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK, INC. via S-3 GROUP
2026 · second_quarter · Q2
Issues related to tariffs and importation of counterfeit drugs.
Issues related to compounding and counterfeit drugs.
Issues related to drug pricing and implementation of the Inflation Reduction Act; coverage of anti-obesity medications; pharmacy benefit management reforms; Most Favored Nation drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Q2
Issues regarding permitting reform
Issues regarding permitting reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JAPAN TOBACCO INTERNATIONAL USA INC. via S-3 GROUP
2026 · second_quarter · Q2
Monitor trade, tax issues and regulations
Monitor trade, tax issues and regulations
Monitor trade, tax issues and regulations
ESSITY NORTH AMERICA INC. via S-3 GROUP
2026 · second_quarter · Q2
Advocacy related to product regulatory issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues regarding lower prescription drug prices for patients
Issues regarding lower prescription drug prices for patients
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OSHKOSH CORPORATION via S-3 GROUP
2026 · second_quarter · Q2
US manufacturing and international competitiveness
US manufacturing and international competitiveness
US manufacturing and international competitiveness
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLOOM ENERGY CORPORATION via S-3 GROUP
2026 · second_quarter · Q2
Issues related to fuel cell tax credits
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COUNCIL ON FOUNDATIONS INC. via S-3 GROUP
2026 · second_quarter · Q2
Strategies and policy advice on tax policy matters with respect to the philanthropic sector
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MONDELEZ INTERNATIONAL via S-3 GROUP
2026 · second_quarter · Q2
Issues related to food and nutrition policy
Issues related to trade, taxes, and tariffs
Issues related to trade, taxes, and tariffs
ABBOTT LABORATORIES via S-3 GROUP
2026 · second_quarter · Q2
Proposals to reform domestic and international tax structures
Equitable Access to Community Pharmacist Services Act
Equitable Access to Community Pharmacist Services Act
PATTERN ENERGY GROUP SERVICES LP via S-3 GROUP
2026 · second_quarter · Q2
Issues regarding renewable energy and electronic transmission projects
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Q2
Issues related to dialysis payment policy, including End Stage Renal Disease (ESRD) Perspective Payment System (PPS)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS INSTITUTE OF TECHNOLOGY via S-3 GROUP
2026 · second_quarter · Q2
Issues related to higher education
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LOWE'S COMPANIES INC. via S-3 GROUP
2026 · second_quarter · Q2
Issues related to corporate tax reform
Issues related to corporate tax reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via S-3 GROUP
2026 · second_quarter · Q2
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Issues related to the provider status of pharmacists under Medicare Part B
Issues related to pharmacy, pharmacist provider status, pharmacy benefit managers, Medicare reimbursement, and pharmaceutical supply chain transparency
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTEL CORPORATION via S-3 GROUP
2026 · second_quarter · Q2
Issues related to support for domestic chipmakers in NDAA
Issues related to semiconductor competitiveness
Issues related to trade and tariffs
ORCHARD THERAPEUTICS NORTH AMERICA via S-3 GROUP
2026 · second_quarter · Q2
Issues related to funding for newborn screenings for metachromatic leukodystrophy
Issues related to funding for newborn screenings for metachromatic leukodystrophy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROCKET LIMITED PARTNERSHIP F/K/A RKT HOLDINGS, LLC via S-3 GROUP
2026 · second_quarter · Q2
General tax reform; qualified office conversion tax credit
Mortgage servicing and data privacy issues; general FHA, FHFA, VA, USDA issues; oversight of federal housing policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to tax filing
Issues related to tax filing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANDOZ INC. via S-3 GROUP
2026 · second_quarter · Q2
Issues and legislative proposals on biosimilars and generics medicines, including but not limited to generics and biosimilar sustainability, pharmaceutical supply chain security, drug shortages, interchangeability, patent litigation, and PBM reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AIR LINE PILOTS ASSOCIATION via S-3 GROUP
2026 · second_quarter · Q2
General aviation issues
General aviation issues
Issues specific to aviation and pilots
BAXTER HEALTHCARE CORPORATION via S-3 GROUP
2026 · second_quarter · Q2
Issues relating to safe mobility; issues relating to pandemic all-hazards preparedness act
Promote kidney care and positive patient outcomes
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONSUMER TECHNOLOGY ASSOCIATION via S-3 GROUP
2026 · second_quarter · Q2
Monitor issues related to consumer data privacy, and children's privacy
General educational meetings on policy issues impacting tech platforms
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE OF COMMUNITY HEALTH PLANS via S-3 GROUP
2026 · second_quarter · Q2
Issues related to healthcare; Medicare Advantage and Medicaid
Issues related to healthcare; Medicare Advantage and Medicaid
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE BUSINESS ROUNDTABLE, INC. via S-3 GROUP
2026 · second_quarter · Q2
Privacy issues
Issues related to corporate and international tax; H.R.1 One Big Beautiful Bill Act of 2025
Tax, trade, economic issues, and government funding
AMERICAN OPTOMETRIC ASSOCIATION via S-3 GROUP
2026 · second_quarter · Q2
Dental and Optometric Care Access Act; Vision Lab Choice Act S 1716
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Q2
General healthcare policy issues, including Medicare Advantage, Medicare Part D and other payer policy matters, and health care clinical services; S.1105: No Unreasonable Payments, Coding, or Diagnoses for the Elderly Act; PL 119-21: One Big Beautiful Bill Act
Issued related to PL 119-21: One Big Beautiful Bill Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FORIS DAX, INC. D/B/A CRYPTO.COM via S-3 GROUP
2026 · second_quarter · Q2
Advocating on behalf of users of cryptocurrency and the process of how consumers invest, save, trade, in the digital place
Advocating on behalf of users of cryptocurrency and the process of how consumers invest, save, trade, in the digital place
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MCKINSEY & COMPANY via S-3 GROUP
2026 · second_quarter · Q2
Raising awareness related to company activities and business
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE TO MODERNIZE PRESCRIBING INFORMATION via S-3 GROUP
2026 · second_quarter · Q2
Advocating for electronic labeling for prescribers only
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAZERAC COMPANY, INC. via S-3 GROUP
2026 · second_quarter · Q2
Issues relating to counterfeit and illegal sales of alcoholic beverages
Issues related to duty drawback and alcohol taxes.
Food and beverage policy issues, including U.S. dietary guidelines; support appropriations or U.S. Alcohol and Tobacco Tax and Trade Bureau; issues pertaining to the alcohol industry.
AMERICAN PETROLEUM INSTITUTE via S-3 GROUP
2026 · second_quarter · Q2
Issues concerning oil and gas production
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. via S-3 GROUP
2026 · second_quarter · Q2
Issues related to health care research
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DUKE ENERGY CORPORATION via S-3 GROUP
2026 · second_quarter · Q2
Regulatory issues confronting the electric utility and natural gas sectors
Regulatory issues confronting the electric utility and natural gas sectors
Regulatory issues confronting the electric utility and natural gas sectors
Issues related to financial services and accounting
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CTIA THE WIRELESS ASSOCIATION via S-3 GROUP
2026 · second_quarter · Q2
Issues related to wireless policy, including spectrum, broadband funding, 5G, and privacy; issues related to the use of contraband phones in correctional facilities; issues related to artificial intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LVMH MOET HENNESSY LOUIS VUITTON INC. via S-3 GROUP
2026 · second_quarter · Q2
Federal policy relating to general tax policy, trade agreements, consumer protection, and general regulatory matters impacting the fashion, wines and spirits, perfume and cosmetic, watch and jewelry, and related luxury products industry
Federal policy relating to general tax policy, trade agreements, consumer protection, and general regulatory matters impacting the fashion, wines and spirits, perfume and cosmetic, watch and jewelry, and related luxury products industry
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, White House Office
JPMORGAN CHASE HOLDINGS LLC via S-3 GROUP
2026 · second_quarter · Q2
Issues related to the budget and the implementation of financial services legislation
Issues related to banking and financial services and Financial Services Appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
XCEL ENERGY SERVICES, INC. via S-3 GROUP
2026 · second_quarter · Q2
Electric and gas utility issues under the tax code and the Federal Power Act, including issues related to renewables
Electric and gas utility issues under the tax code and the Federal Power Act, including issues related to renewables
Electric and gas utility issues under the tax code and the Federal Power Act, including issues related to renewables
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S&P GLOBAL via S-3 GROUP
2026 · second_quarter · Q2
Issues related to the pricing of aluminum
Issues related to credit rating agencies and commodity/ financial derivatives and benchmarks; privacy issues
Issues related to infrastructure
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KOCH GOVERNMENT AFFAIRS, LLC FKA KOCH COMPANIES PUBLIC SECTOR, LLC via S-3 GROUP
2026 · second_quarter · Q2
Legislative issues related to energy and the environment; issues related to congressional funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONSTELLATION BRANDS via S-3 GROUP
2026 · second_quarter · RR
Commercial issues related to the beverage alcohol industry
NOVO NORDISK, INC. via S-3 GROUP
2026 · first_quarter · Q1
Issues related to drug pricing and implementation of the Inflation Reduction Act; coverage of anti-obesity medications; pharmacy benefit management reforms; Most Favored Nation drug pricing.
Issues related to tariffs and importation of counterfeit drugs.
Issues related to compounding and counterfeit drugs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Q1
Issues regarding permitting reform
Issues regarding permitting reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JAPAN TOBACCO INTERNATIONAL USA INC. via S-3 GROUP
2026 · first_quarter · Q1
Monitor trade, tax issues and regulations
Monitor trade, tax issues and regulations
Monitor trade, tax issues and regulations
ESSITY NORTH AMERICA INC. via S-3 GROUP
2026 · first_quarter · Q1
Advocacy related to product regulatory issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues regarding lower prescription drug prices for patients
Issues regarding lower prescription drug prices for patients
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OSHKOSH CORPORATION via S-3 GROUP
2026 · first_quarter · Q1
US manufacturing and international competitiveness
US manufacturing and international competitiveness
US manufacturing and international competitiveness
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLOOM ENERGY CORPORATION via S-3 GROUP
2026 · first_quarter · Q1
Issues related to fuel cell tax credits
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COUNCIL ON FOUNDATIONS INC. via S-3 GROUP
2026 · first_quarter · Q1
Strategies and policy advice on tax policy matters with respect to the philanthropic sector
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to trade, taxes, and tariffs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Equitable Access to Community Pharmacist Services Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to R&D tax credit
Issues related to funding for CHIPS Act
Issues related to semiconductor competitiveness
Issues in support for STEM
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General aviation issues
Issues relating to No Tax On Overtime provision
Issues involving mandatory retirement age for pilots
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to corporate and international tax
Issues relating to capital allocation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
H.R. 2405 (White Oak Resilience Act) and S. 476 (White Oak Resilience Act) relating to the availability of white oak; forestry-related provisions in agriculture-related legislation; H.R. 471 (Fix Our Forests Act); issues related to intoxicating hemp
Issues relating to counterfeit and illegal sales of alcoholic beverages
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Regulatory issues confronting the electric utility and natural gas sectors
Regulatory issues confronting the electric utility and natural gas sectors
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Monitor trade, tax issues and regulations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to food and nutrition policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to infant formula
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to funding for CHIPS Act
Issues related to R&D tax credit
Issues in support for STEM
Issues related to Inter Partes Review and patent litigation at the ITC
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues relating to No Tax On Overtime provision
Aviation safety; single pilot operations
Issues involving mandatory retirement age for pilots
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues relating to artificial intelligence
Issues related to trade and tariff policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Proposed tariffs and impact on exports and imports of distilled spirits.
H.R. 2405 (White Oak Resilience Act) and S. 476 (White Oak Resilience Act) relating to the availability of white oak; forestry-related provisions in agriculture-related legislation; H.R. 471 (Fix Our Forests Act); issues related to intoxicating hemp
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Regulatory issues confronting the electric utility and natural gas sectors
Regulatory issues confronting the electric utility and natural gas sectors
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Monitor trade, tax issues and regulations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE